Skip to content

Trial to Evaluate the Safety and Effectiveness of Vagus Nerve Stimulation for Children With Refractory Epilepsy

Vagus Nerve Stimulation for Pediatric Intractable Epilepsy (VNS-PIE)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03062514
Enrollment
84
Registered
2017-02-23
Start date
2017-10-09
Completion date
2019-12-31
Last updated
2018-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Epilepsy

Brief summary

Children with refractory epilepsy who are candidates for a treatment with vagus nerve stimulation will be prospectively randomized into 2 arms. Vagus nerve stimulation parameters are programmed and adjusted during outpatient clinic visits, within the normal clinical practice.

Interventions

DEVICEPINS Vagus Nerve Stimualtor

PINS Vagus Nerve Stimualtor

Sponsors

Beijing Pins Medical Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

1. Age 3-6 2. At least 6 seizure per month 3. Refractory Epilepsy 4. In good health except epilepsy 5. Patients or his(her) familyscould understand this method and sign the informed consent 6. Patients with good compliance and could complete postoperative follow-up

Exclusion criteria

1. Results of MRI remind epilepsy caused by intracranial space-occupying lesions 2. The vagus nerve lesion and damage 3. Tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma,mental disease,pepticulcer,diabetes,bad health etc, and other surgical contraindication 4. Cann't write the epilepsy diary 5. Participating other clinical trial 6. Cann't complate the operation 7. Complete the postoperative follow-up 8. Cann't complete the promgramming

Design outcomes

Primary

MeasureTime frame
Changes in seizure frequency12 weeks of stimulation

Secondary

MeasureTime frame
Changes in seizure frequency6、12、24 weeks of stimulation
Engel scale description6、12、24 weeks of stimulation
Changes in the Number of Anti-epileptic Drugs6、12、24 weeks of stimulation
GESELL mental development scales12、24 weeks of stimulation

Countries

China

Contacts

Primary ContactFumin Jia, PhD
pins_medical@163.con010-60736388
Backup ContactLuming Li, PhD
010-80699200

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026